✦ LIBER ✦

502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623

✍ Scribed by Choo, E.; Belvin, M.; Merchant, M.; Chan, E.; Hollingshead, P.; Orr, C.; Boggs, J.; Plise, E.; Robarge, K.; Zak, M.

Book ID: 122751869
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 60 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(12)72299-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preclinical pharmacokinetics and pharmac

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

✍ Kan He; Joseph M. Luettgen; Donglu Zhang; Bing He; James E. Grace; Baomin Xin; D 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 366 KB

SB-239063, a Potent and Selective Inhibi

SB-239063, a Potent and Selective Inhibitor of P38 Map Kinase: Preclinical Pharmacokinetics and Species-Specific Reversible Isomerization

✍ Keith W. Ward; Joel W. Proksch; Leonard M. Azzarano; Kevin L. Salyers; Jeanelle 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 303 KB

COMPOUND 1, A POTENT AND SELECTIVE DAO I

COMPOUND 1, A POTENT AND SELECTIVE DAO INHIBITOR, DEMONSTRATES EFFICACY IN SEVERAL PRECLINICAL ANIMAL MODELS OF SCHIZOPHRENIA

✍ Steven Grauer; Paul Dollings; Michael Popiolek; Mark Pausch; Joseph Zaccardi; Ju 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Preclinical Assessment of the Absorption

Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human

✍ Salphati, L.; Pang, J.; Plise, E. G.; Lee, L. B.; Olivero, A. G.; Prior, W. W.; 📂 Article 📅 2012 🏛 American Society for Pharmacology and Experimental 🌐 English ⚖ 877 KB

79 Preclinical pharmacokinetic evaluatio

79 Preclinical pharmacokinetic evaluation of selected members of a new class of potent HIV-1 reverse transcriptase inhibitors: C. Sahlberg1, B.-L. Sahlberg2, K. Frykman2, M. Clemens3, J. S. Kasher3, J. M. Morin, Jr.3, R. J. Ternansky3, F. W. Bell3, C. L. Jordan3, M. D. Kinnick3, J. A. Palkowitz3, C. A. Parrish3, P. Pranc3, R. T. Vasileff3, and S. J. West3. 1Medivir AB, Huddinge, Sweden; Apoteksbolaget Central Laboratory, Stockholm, Sweden; 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 81 KB